LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Recursion Pharmaceuticals Inc

Închisă

SectorSănătate

4.56 7.55

Rezumat

Modificarea prețului

24h

Curent

Minim

4.25

Maxim

4.63

Indicatori cheie

By Trading Economics

Venit

-24M

-202M

Vânzări

10M

15M

EPS

-0.5

Marjă de profit

-1,373.259

Angajați

800

EBITDA

-26M

-191M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+56.61% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-431M

1.9B

Deschiderea anterioară

-2.99

Închiderea anterioară

4.56

Sentimentul știrilor

By Acuity

100%

0%

371 / 382 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

16 mai 2025, 19:39 UTC

Principalele dinamici ale pieței

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

16 mai 2025, 23:18 UTC

Top știri

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 mai 2025, 22:30 UTC

Top știri

U.S. Loses Last Triple-A Credit Rating -- Update

16 mai 2025, 21:56 UTC

Market Talk

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 mai 2025, 21:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 mai 2025, 21:54 UTC

Top știri

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 mai 2025, 21:22 UTC

Market Talk

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 mai 2025, 21:17 UTC

Market Talk

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 mai 2025, 21:17 UTC

Top știri

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 mai 2025, 21:05 UTC

Market Talk

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 mai 2025, 20:55 UTC

Achiziții, Fuziuni, Preluări

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mai 2025, 20:50 UTC

Market Talk
Câștiguri

Financial Services Roundup: Market Talk

16 mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 mai 2025, 20:37 UTC

Top știri

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 mai 2025, 20:33 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 mai 2025, 20:30 UTC

Achiziții, Fuziuni, Preluări

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 mai 2025, 20:18 UTC

Top știri

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 mai 2025, 20:16 UTC

Top știri

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 mai 2025, 20:15 UTC

Câștiguri

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 mai 2025, 20:11 UTC

Achiziții, Fuziuni, Preluări

Henry Schein: William K. Daniel Joins Board

16 mai 2025, 20:10 UTC

Achiziții, Fuziuni, Preluări

Henry Schein: Strategic Investment by KKR Completed

16 mai 2025, 20:05 UTC

Achiziții, Fuziuni, Preluări

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mai 2025, 19:38 UTC

Market Talk

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16 mai 2025, 19:07 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

16 mai 2025, 18:51 UTC

Top știri

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16 mai 2025, 18:41 UTC

Achiziții, Fuziuni, Preluări

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mai 2025, 18:37 UTC

Market Talk

Gold Futures End Week on Negative Note -- Market Talk

16 mai 2025, 18:35 UTC

Top știri

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 mai 2025, 18:32 UTC

Top știri

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

16 mai 2025, 18:28 UTC

Market Talk

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Comparație

Modificare preț

Recursion Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

56.61% sus

Prognoză pe 12 luni

Medie 6.75 USD  56.61%

Maxim 8 USD

Minim 3 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRecursion Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

5 ratings

1

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

4.15 / 4.75Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

371 / 382 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.